Turn Therapeutics Eyes Nasdaq Direct Listing for PermaFusion Platform

TL;DR

**TTRX's direct listing is a high-risk, high-reward play on a promising drug delivery platform, but expect volatility and founder-centric control.**

AI Summary

Global Health Solutions, Inc. (soon to be Turn Therapeutics Inc.) is a pharmaceutical and medical device development company leveraging its proprietary PermaFusion platform to enhance drug performance by enabling stable suspension of water-soluble active pharmaceutical ingredients in oil-based carriers without emulsifiers. This innovation improves bioavailability and reduces API load, thereby decreasing the likelihood of adverse events. The company's Hexagen formula, derived from this platform, has received three FDA 510(k) clearances (K160872 in November 2016, K171191 in August 2017, and K183681 in October 2019) for wound care and various skin conditions, demonstrating technical proof of concept and therapeutic effects. While these FDA-cleared devices are not currently generating revenue, the company is focusing on drug development, particularly for dermatological diseases like eczema and onychomycosis. Additionally, Turn Therapeutics is exploring broader applications, including a partnership to develop thermostable intranasal vaccines and has completed preclinical in-vivo xenograft studies showing an 85% reduction in viral load for herpes zoster ophthalmicus and an approximate 20% comparative reduction in tumor size for basal cell carcinoma with Hexagen. The company is pursuing a direct listing on Nasdaq under the symbol "TTRX" for 17,868,760 shares, with no proceeds from the resale going to the company.

Why It Matters

This S-1/A filing signals Global Health Solutions' pivot to a direct listing as Turn Therapeutics Inc. on Nasdaq, offering investors a chance to participate in a company with a validated proprietary drug delivery platform, PermaFusion. The company's FDA-cleared Hexagen formula and promising preclinical results in dermatology and vaccine development suggest significant market potential, challenging existing treatments by improving drug efficacy and reducing side effects. However, the direct listing without an underwriter could lead to higher price volatility, impacting early investors and potentially affecting employee stock options. The founder's majority control also raises governance concerns, differentiating it from competitors with more dispersed ownership.

Risk Assessment

Risk Level: high — The company explicitly states, "No public market for our common stock currently exists" and that the direct listing is "a less typical method for commencing public trading... consequently, the trading volume and price of shares of our common stock may be more volatile." Furthermore, the founder and CEO will control "more than 50% of our outstanding shares of common stock on a fully diluted basis," leading to "substantial control over our business," which poses a significant governance risk to other shareholders.

Analyst Insight

Investors should approach TTRX with caution, recognizing the inherent volatility of a direct listing and the significant founder control. Conduct thorough due diligence on the PermaFusion platform's clinical trial progress and market adoption potential, as the company is not currently generating revenue from its FDA-cleared devices.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

$1,000,000

total Debt

$0

net Income

-$1,548,000

eps

N/A

gross Margin

N/A

cash Position

$10,000

revenue Growth

N/A

Executive Compensation

Key Numbers

• 17,868,760 Shares — Common stock registered for resale (Represents the total shares Registered Stockholders may sell, with no proceeds to the company.)
• $11.65 — Regulation A offering price per share (Price at which 41,805 shares were sold between March 31, 2025, and June 27, 2025, prior to the Stock Split.)
• 41,805 shares — Shares sold in Regulation A offering (Issued and sold without giving effect to the 2-for-1 Stock Split.)
• 2-for-1 — Forward stock split ratio (To be effectuated immediately prior to the effectiveness of the registration statement.)
• 50% — Founder's ownership control (Bradley Burnam will control more than 50% of outstanding shares on a fully diluted basis.)
• 85% — Reduction in viral load (Achieved in preclinical in-vivo xenograft studies for herpes zoster ophthalmicus compared to placebo.)
• 29% — Comparative reduction in tumor size (Achieved by Hexagen formula for basal cell carcinoma compared to placebo in preclinical studies.)
• 20% — Comparative reduction in tumor size (Achieved by Hexagen formula for basal cell carcinoma compared to 5-Fluorouracil in preclinical studies.)
• K160872 — FDA 510(k) clearance (Obtained in November 2016 for Hexagen formula under product category FRO.)
• K171191 — FDA 510(k) clearance (Granted in August 2017 for managing skin conditions including dermatitis.)

Key Players & Entities

• Global Health Solutions, Inc. (company) — Registrant, soon to be Turn Therapeutics Inc.
• Turn Therapeutics Inc. (company) — New name of the Registrant
• Bradley Burnam (person) — Chief Executive Officer and founder, controlling over 50% of shares
• Nasdaq Global Market (regulator) — Intended listing exchange for TTRX
• Clear Street LLC (company) — Financial advisor for the direct listing
• Securities and Exchange Commission (regulator) — Regulatory body for the S-1/A filing
• Davis Polk & Wardwell LLP (company) — Legal counsel for the Registrant
• Michael Kaplan (person) — Counsel at Davis Polk & Wardwell LLP
• Stephen A. Byeff (person) — Counsel at Davis Polk & Wardwell LLP
• Delaware (regulator) — State of incorporation

FAQ

Risk Factors

• Limited Operating History and History of Losses [high — financial]: The company has a limited operating history and has incurred significant net losses since its inception. For the year ended December 31, 2023, the company reported a net loss of $1,548,000. This history of losses raises substantial doubt about the company's ability to continue as a going concern.
• Reliance on FDA Approvals for Future Products [high — regulatory]: The company's future revenue generation is dependent on the successful development and FDA approval of new drug candidates. While Hexagen has received 510(k) clearances for wound care, these are not currently generating revenue. Obtaining approval for new drug applications (NDAs) is a lengthy and uncertain process.
• Dependence on Key Personnel [medium — operational]: The success of the company is heavily reliant on the expertise of its key management and scientific personnel, including Bradley Burnam. The loss of any of these individuals could materially and adversely affect the company's ability to execute its business plan.
• Competition in Pharmaceutical and Medical Device Markets [medium — market]: The markets for dermatological treatments and medical devices are highly competitive, with numerous established companies and emerging players. The company faces competition from companies with greater financial resources and established market presence.
• Need for Additional Funding [high — financial]: The company has historically relied on external financing to fund its operations and development activities. It anticipates requiring additional capital to fund its ongoing research and development, clinical trials, and commercialization efforts. There is no assurance that such funding will be available on acceptable terms.
• Intellectual Property Risks [medium — regulatory]: The company's ability to protect its proprietary PermaFusion platform and Hexagen formula is critical. The company may face challenges in obtaining and enforcing patent protection, and competitors may develop similar technologies or challenge existing patents.
• Manufacturing and Supply Chain Risks [low — operational]: The company will need to establish and manage reliable manufacturing processes and supply chains for its products. Any disruptions or quality control issues in manufacturing could impact product availability and regulatory compliance.
• Potential Litigation [low — legal]: As a development-stage company, it may be subject to various legal proceedings, including intellectual property disputes, product liability claims, or employment-related litigation, which could result in significant financial liabilities.

Industry Context

The pharmaceutical and medical device industries are characterized by high R&D costs, lengthy development cycles, and stringent regulatory oversight. The dermatological market, in particular, is competitive with established players and a growing demand for innovative treatments. Trends include a focus on targeted therapies, improved drug delivery systems, and non-invasive treatment options.

Regulatory Implications

The company's success hinges on navigating the FDA's regulatory pathways for drug and device approvals. While 510(k) clearances for Hexagen demonstrate a degree of regulatory acceptance, future drug development will require more rigorous New Drug Application (NDA) processes, which are costly and time-consuming.

What Investors Should Do

1. Monitor FDA progress for new drug candidates.
2. Assess cash burn rate and future funding needs.
3. Evaluate competitive landscape and market penetration strategy.
4. Analyze the impact of the direct listing and founder's control.

Key Dates

• 2016-11-01: FDA 510(k) clearance for Hexagen (K160872) — Demonstrated initial FDA acceptance for the Hexagen formula in wound care, validating the PermaFusion platform's potential.
• 2017-08-01: FDA 510(k) clearance for Hexagen (K171191) — Expanded the FDA clearance for Hexagen to include management of skin conditions, broadening its potential applications.
• 2019-10-01: FDA 510(k) clearance for Hexagen (K183681) — Further FDA clearance for Hexagen, indicating continued validation of the technology for various skin-related applications.
• 2025-03-31: Start of Regulation A offering — Marks the beginning of a period where the company sold shares at $11.65 prior to a stock split, indicating early-stage capital raising efforts.
• 2025-06-27: End of Regulation A offering — Concludes the period of share sales under Regulation A, providing a snapshot of early investor participation.

Glossary

PermaFusion platform

A proprietary technology that allows stable suspension of water-soluble active pharmaceutical ingredients (APIs) in oil-based carriers without the need for emulsifiers. (This is the core technology of Global Health Solutions, Inc. (Turn Therapeutics Inc.), enabling enhanced drug delivery and performance.)

API

Active Pharmaceutical Ingredient, the biologically active component of a drug product. (The platform aims to improve the delivery and efficacy of APIs, potentially reducing the required dosage and side effects.)

Bioavailability

The proportion of a drug or other substance which enters the circulation when introduced into the body and so is able to have an effect. (The PermaFusion platform is designed to enhance bioavailability, meaning more of the drug reaches its target in the body.)

FDA 510(k) clearance

A premarket submission made to the U.S. Food and Drug Administration (FDA) to demonstrate that the device to be marketed is at least as safe and effective, that is, substantially equivalent, to a legally marketed device. (The company has obtained three such clearances for its Hexagen formula, indicating regulatory acceptance for specific medical device applications.)

Regulation A offering

A U.S. securities regulation that exempts certain small offerings from registration requirements, allowing companies to raise capital from the public. (The company utilized this to sell 41,805 shares prior to its direct listing, providing an early indication of valuation.)

Stock Split

A corporate action in which a company divides its existing shares into multiple shares, increasing the number of shares outstanding but reducing the value per share proportionally. (A 2-for-1 stock split is planned immediately prior to the effectiveness of the registration statement, impacting the share count and per-share metrics.)

Xenograft studies

A type of experiment where tissues or cells from one species are transplanted into a host of another species. (Preclinical xenograft studies have been conducted to evaluate the efficacy of Hexagen, showing promising results for viral load reduction and tumor size.)

Direct Listing

A method for a private company to become publicly traded without the need for an underwriter, typically involving the sale of existing shares by current shareholders. (The company is pursuing a direct listing on Nasdaq, meaning the 17,868,760 shares registered for resale are by existing stockholders, not for raising new capital for the company.)

Year-Over-Year Comparison

This S-1/A filing represents a significant update as the company prepares for its direct listing. Unlike previous filings that might have focused on early-stage development and regulatory milestones, this document details the planned direct listing of 17,868,760 shares by existing stockholders. Financials show a net loss of $1,548,000 for the year ended December 31, 2023, with minimal cash reserves of $10,000, highlighting the ongoing need for capital. Key risks related to funding, regulatory approval for new drugs, and operational history remain prominent.

Key Financial Figures

• $0.0001 — 0 shares of our common stock, par value $0.0001 per share (the "common stock") by the s
• $11.65 — ies Act") at a public offering price of $11.65 per share, which concluded on June 27,

Filing Documents

• tm2518292-11_s1a.htm (S-1/A) — 2288KB
• tm2518292d13_ex5-1.htm (EX-5.1) — 10KB
• tm2518292d13_ex10-12.htm (EX-10.12) — 16KB
• tm2518292d13_ex23-1.htm (EX-23.1) — 3KB
• tm2518292d11_ex-filingfees.htm (EX-FILING FEES) — 25KB
• lg_turntherapeutics-4clr.jpg (GRAPHIC) — 24KB
• fc_roadmap-4clr.jpg (GRAPHIC) — 93KB
• lg_withumaudit-4c.jpg (GRAPHIC) — 14KB
• ft_withumsmithbrown-4c.jpg (GRAPHIC) — 24KB
• sg_withumsmithbrown-bw.jpg (GRAPHIC) — 8KB
• tm2518292d13_ex5-1img001.jpg (GRAPHIC) — 6KB
• 0001104659-25-092994.txt ( ) — 2690KB
• tm2518292d11_ex-filingfees_htm.xml (XML) — 5KB

Risk Factors

Risk Factors 20 Special Note Regarding Forward-Looking Statements 56

Use of Proceeds

Use of Proceeds 57 Dividend Policy 58 Capitalization 59

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 60

Business

Business 70 Management 90 Executive and Director Compensation 94 Certain Relationships and Related Party Transactions 100 Principal and Registered Stockholders 102

Description of Capital Stock

Description of Capital Stock 105 Material U.S. Federal Income and Estate Tax Consequences to Non-U.S. Holders of Our Common Stock 111 Shares Eligible for Future Sale 116 Sale Price History of Our Capital Stock 119 Plan of Distribution 120 Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 124 Legal Matters 124 Experts 124 Where You Can Find More Information 124 Index to Consolidated Financial Statements F-1 In this prospectus, "Turn Therapeutics," "Global Health Solutions," the "Company," "we," "us" and "our" refer to Global Health Solutions, Inc., dba Turn Therapeutics and its consolidated subsidiaries. Immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, we intend to change our name to Turn Therapeutics Inc. Neither we nor any of the Registered Stockholders have authorized anyone to provide any information different from, or in addition to, the information contained in this prospectus and in any free writing prospectuses we have prepared. Neither we nor any of the Registered Stockholders take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. The Registered Stockholders are offering to sell, and seeking offers to buy, shares of their common stock only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of its date, regardless of the time of delivery of this prospectus or of any sale of our common stock. Our business, financial condition, results of operations and prospects may have changed since such date. This prospectus includes industry and market data that we obtained from periodic industry publications, third-party studies and surveys, filings of public companies in our industry and internal company surveys. These sources include government and industry sources. Industry publicat

View Full Filing

View this S-1/A filing on SEC EDGAR